Clinical trials: XEROSTOMIA
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome
- Trial name
- NCT06417398
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Primary Sjögren's Syndrome (pSS)
Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome
This is a phase2a, multicenter, double-blind, placebo control, randomized study to investigate the efficacy and safety of SA001 in subjects with pSS.
- Trial name
- NCT05269810
- Testing
- SA001 Low dose, SA001 Mid dose, SA001 High dose
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Dry Mouth
Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601211
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Xerostomia
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
This will be a single center, 7-day, examiner blind, two treatment-arm, randomized, stratified (Sjogren's Syndrome status [Y/N]), parallel group study conducted in participants experiencing dry mouth symptoms.
- Trial name
- NCT02641912
- Testing
- Biotene mouthwash, Mineral Water
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dry Mouth
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
- Trial name
- NCT01903122
- Testing
- Cevimeline
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Sjogren Disease
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
- Trial name
- EnVISage (NCT06928142)
- Testing
- Sibeprenlimab
- Where
- 64 sites in United States, Argentina and 6 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2
The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with…
- Trial name
- NCT03452085
- Testing
- artificial saliva spray (AS), maritime throat spray (TT)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Certmedica International GmbH
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Dry Mouth, Xerostomia
"Hyaluronan" Formulation for Type 2 Diabetic Patients With Dry Mouth
An increased incidence of dental caries in association with poorly controlled diabetes has also been reported, Xerostomia (dry mouth) has been reported to be a common complaint of patients with diabetes, Without adequate saliva…
- Conditions
- Dry Mouth, Xerostomia, Type 2 Diabetics
- Trial name
- NCT03281486
- Testing
- HA formulation Oral Spray
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- You First Services
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Xerostomia
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
The objective of the trial was to evaluate the efficacy and clinical safety and acceptability of Oxygenated Glycerol Triesters in the relief of symptoms of xerostomia versus a reference comparator.
- Trial name
- NCT00332618
- Testing
- OXYGENATED GLYCEROL TRIESTERS
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Laboratoires CARILENE
Xerostomia
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
This study assessed the efficacy of three dry mouth products (including an experimental Oralbalance gel, oral rinse, and moisturizing spray) to relieve the feeling of dry mouth compared to water, in dry mouth population over a…
- Trial name
- NCT03494985
- Testing
- Experimental Oralbalance Moisturizing Gel, Biotene Original Oral Rinse, Biotene Moisturizing Mouth Spray
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Xerostomia
Clinical Evaluation of Oral Rinse for Xerostomia
Xerostomia causes a difficulty in eating, have irritated oral tissues, and a poor quality of life. The new oral rinse was designed to reduce the symptoms and improve the patient's quality of life.
- Trial name
- NCT04289051
- Testing
- HYDRAL Oral Rinse, BIOTENE® Oral Rinse
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sunstar Americas
Sjogren Syndrome
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Treatment Method for Sjogren's Syndrome (SS)
The purpose of the study is to investigate the effect and safety of the Walther System delivering INMEST (intranasal mechanical stimulation) on people with Sjogren\'s syndrome.
- Trial name
- A-SS-001 (NCT06626477)
- Testing
- Intra nasal mechanical stimulation treatment (INMEST)
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Abilion Medical Systems AB
Dry Eye Disease, Sjögren Syndrome
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to…
- Trial name
- NCT04819269
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 46 sites in United States, Spain
- Volunteers
- 203 people
- Sponsor
- Sylentis, S.A.
Healthy, Sicca Syndrome
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
The main objective of the study is to characterize the gene expression in immune and epithelial cells in salivary gland biopsy samples and blood of pSS (primary Sjögren's syndrome) and non-pSS participants including healthy…
- Conditions
- Healthy, Sicca Syndrome, Sjögren's Syndrome
- Trial name
- NCT02422407
- Testing
- Biopsy
- Where
- 4 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Biogen
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS)
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular…
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- in vivo CAR-T (NCT07413341)
- Testing
- TI-0032-III injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Systemic Lupus Erythematosus, Sjogren's Syndrome
Clinical Performance of BioCLIA Ro60
The study is to evaluate the clinical performance of BioCLIA Ro60 for measuring the autoantibody in autoimmune disease patients.
- Trial name
- NCT03204448
- Testing
- BioCLIA Ro60
- Where
- United States
- Sponsor
- HOB Biotech Group